Open AccessThe anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
Author(s) -
Yue Xi,
Yanping Li,
Pengfei Xu,
Sihan Li,
Zhengsheng Liu,
HungChun Tung,
Xinran Cai,
Jingyuan Wang,
Haozhe Huang,
Menglin Wang,
Meishu Xu,
Songrong Ren,
Song Li,
Min Zhang,
Yong J. Lee,
Leaf Huang,
Da Yang,
Jinhan He,
Zhiying Huang,
Wen Xie
Publication year - 2021
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.abg9241
Subject(s) - glutaredoxin , pirfenidone , fibrosis , allicin , cancer research , chemistry , glutathione , medicine , idiopathic pulmonary fibrosis , biochemistry , enzyme , pathology , lung
Pirfenidone inhibits HSC activation and liver fibrosis by targeting glutaredoxin-1 and reducing Smad3 glutathionylation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom